5:59 PM
 | 
Oct 03, 2012
 |  BC Extra  |  Company News

Germany: no added benefit for Teysuno in gastric cancer

Germany's Federal Joint Committee (G-BA) said in a preliminary benefit assessment that Teysuno tegafur/gimeracil/oteracil from Nordic Group (Paris, France) offers no additional benefit over Xeloda capecitabine or 5-fluorouracil (5-FU) as first-line treatment of...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >